Precision Cell Systems Acquires BennuBio to Enter the 3D Cell Culture Market
LIVERMORE, Calif., Oct. 1, 2025 /PRNewswire/ — Precision Cell Systems (PCS) today announced the acquisition of BennuBio, marking a significant entry into the rapidly growing 3D cell culture market. According to Grand View Research, the global market was valued at over $1.7 billion and is projected to exceed $3.2 billion by 2030. The acquisition brings BennuBio’s Velocyt™ imaging flow cytometer into the PCS portfolio, expanding the company’s capabilities in single-cell analysis, cell therapy, drug discovery, and bioprocessing applications.
BennuBio is a New Mexico-based life science company that has developed an imaging flow cytometer for high-throughput analysis of 3D multicellular models including spheroids, organoids, and stem cell aggregates. The Velocyt platform addresses a critical unmet need by rapidly characterizing large particles beyond the capabilities of standard flow cytometry while enabling complete sample recovery for downstream analysis.
